#USA #biotechnology #Skanska #Charlottesville

Skanska Secures New Contract for Biotechnology Facility

Introduction
In a significant development in the biotechnology sector, Skanska has announced the signing of a major contract with the University of Virginia. This agreement, valued at $66 million, aims to construct the Paul and Diane Manning Institute of Biotechnology located in Charlottesville, Virginia. The decision marks a substantial investment in the region's research capabilities and will further elevate the state's standing in the field of biotechnology.

Project Overview
The Paul and Diane Manning Institute of Biotechnology will be established at the Fontaine Research Park, showcasing state-of-the-art facilities designed to foster innovative research and collaboration. The project includes a five-story building spanning approximately 33,000 square meters (or 354,000 square feet).
Once completed, this facility will house groundbreaking translational research programs that are unprecedented in Virginia.

Facility Features
This new institute is designed specifically for modern research needs, featuring:

• - Modular, Multi-Use Laboratory Space: Providing flexible environments for various types of research
• - Core Facilities: Super-equipped to handle essential research functions across disciplines
• - Support Areas: Designed for administrative and collaborative activities
• - Collaboration Space: Accommodating 100-150 researchers and partnering biotechnology firms to enhance synergies in scientific advancements

Such features will provide a dynamic and effective research environment that encourages innovation and partnerships at the frontier of biotechnology.

Construction Timeline
The groundwork for this project began in December 2023 and is anticipated to be completed by the fourth quarter of 2027. As part of Skanska's commitment to sustainability and innovation, the construction will adhere to the highest standards of environmental and engineering practices.
This timeline indicates a robust planning phase, ensuring that the facility will be equipped with the latest technologies upon its opening.

Future Impacts
The establishment of the Paul and Diane Manning Institute of Biotechnology stands to significantly impact not only the local economy but also the broader scientific community. By cultivating a hub for biotechnology research, the institute is poised to attract talent and investment, thereby contributing to advancements in health care and technology. Collaborative efforts between researchers and biotechnology companies will pave the way for new discoveries and innovations that address some of the most pressing challenges in health and medicine.
Furthermore, this project embodies Skanska's strategic goals of engaging in projects that foster community growth and technological leads in the contemporary economy.

Conclusion
As Skanska moves forward with this ambitious project, the biotechnology landscape in Charlottesville is set to transform. The Paul and Diane Manning Institute of Biotechnology will not only promote scientific research but will also serve as a catalyst for economic growth and technological innovation in Virginia. Stakeholders eagerly anticipate the benefits this facility will bring once it opens its doors in late 2027, heralding a new era in biotechnology research and collaboration.
For more information, please contact:

• - Ashley Jeffery, Communications Manager, USA Building, tel: +1 813 459 3682
• - Andreas Joons, Press Officer, Skanska Group, tel: +46 76 870 75 51
• - Direct line for media, tel: +46 (0)10 448 88 99

You can follow updates related to this project and others by visiting Skanska's official website.